...“If you look at 340B, the majority of the exposure really is for products like Januvia...

...the future, and the company expects to continue exploring the cardiometabolic area. Diabetes drug Januvia sitagliptin...

...apixaban by 6%, and Merck & Co. Inc. (NYSE:MRK) raised the list price of Januvia sitagliptin...

...drug Rybelsus oral semaglutide from Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) is superior to Januvia sitagliptin...

...to report Phase I data for its U.S. trials of dorzagliatin plus DPP-4 inhibitor Januvia sitagliptin...
...Co. (NYSE:LLY). The company will also start a Chinese Phase III study comparing dorzagliatin and Januvia...

...has a wholesale acquisition cost (WAC) of $772.43 per month. Oral diabetes drug competitors Januvia sitagliptin...

...chronic indications to help the pharma weather any revenue shortcomings when its diabetes drug Januvia sitagliptin...
...and provided insight into its appetite for M&A. "Everything we need to drive growth through Januvia...
...day Thursday. Merck & Co. Inc. (NYSE:MRK) recorded $5.9 billion in 2018 sales for the Januvia...

...began a Phase I trial of its dorzagliatin (sinogliatin, HMS5552, RO5305552) in combination with Januvia sitagliptin...
...a small molecule GCK activator, from Roche (SIX:ROG; OTCQX:RHHBY). Merck & Co. Inc. (NYSE:MRK) markets Januvia...

...I’m one of these consolidated payers and I’ve contracted with Merck & Co. Inc. for Januvia...

...greater proportion of patients who achieved an HbA1c of <7% at week 52 vs. Januvia sitagliptin...
...for Januvia. Additionally, oral semaglutide significantly reduced body weight from baseline to week 52 vs. Januvia...
...Status: Phase IIIa data Milestone: Submit regulatory application (2019) Jennie Walters Glactiv, Januvia, Tesavel, sitagliptin (MK-0431, MK-431, ONO-5435) Jardiance...